Trial Underway to Provide Scientific Validity of the Analgesic Efficacy …

SASKATOON, Saskatchewan WINNIPEG, Manitoba–(BUSINESS WIRE)–As one of the major symptoms experienced by patients with Multiple
Sclerosis (MS), neuropathic pain can be extremely debilitating. A
leading neuro-immunology team lead by Dr. Michael Namaka at the
University of Manitoba in Winnipeg, Manitoba, is looking to determine
the analgesic efficacy of two of CanniMed Therapeutics Inc. (TSX: CMED)
cannabinoid plant derived oil extracts using a rodent model of
MS-induced neuropathic pain.

The study entitled Identifying the molecular mechanisms involved in
supressing multiple sclerosis induced neuropathic pain following
cannabinoid treatment in

... read more at: